Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Cash from Financing Activities (2017 - 2025)

Puma Biotechnology's Cash from Financing Activities history spans 8 years, with the latest figure at -$11.3 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities changed 0.01% year-over-year to -$11.3 million; the TTM value through Dec 2025 reached -$45.2 million, down 33.54%, while the annual FY2025 figure was -$45.2 million, 33.54% down from the prior year.
  • Cash from Financing Activities reached -$11.3 million in Q4 2025 per PBYI's latest filing, roughly flat from -$11.3 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $9.8 million in Q1 2022 to a low of -$31.9 million in Q3 2021.
  • Average Cash from Financing Activities over 4 years is -$8.2 million, with a median of -$11.3 million recorded in 2024.
  • Peak YoY movement for Cash from Financing Activities: crashed 74353.49% in 2021, then surged 121650.0% in 2022.
  • A 4-year view of Cash from Financing Activities shows it stood at -$2000.0 in 2021, then soared by 121650.0% to $2.4 million in 2022, then crashed by 566.1% to -$11.3 million in 2024, then decreased by 0.01% to -$11.3 million in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Cash from Financing Activities are -$11.3 million (Q4 2025), -$11.3 million (Q3 2025), and -$11.2 million (Q2 2025).